SEC Form 4 · accession 0001144204-16-106073
Tonix Pharmaceuticals Holding Corp. · TNXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley Saenger
Officer — Chief Financial Officer
Period of report
May 27, 2016
Accepted (ET)
May 31, 2016 · 9:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F1 | $2.42 | May 27, 2016 | A | 20,000 | A | — | May 27, 2026 | Common Stock | 20,000 | 20,000 | D |
| Stock OptionF2,F3 | $2.42 | May 27, 2016 | A | 60,000 | A | — | May 27, 2026 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2The option was granted pursuant to the Issuer's 2016 Stock Incentive Plan.
- F3The option vests 1/3rd upon the date(s) that certain stock price goals are achieved. The stock price goals are such date(s) when the Issuer's common stock has an average closing sales price equal to or exceeding each of $6.00, $7.00 and $8.00 per share for 20 consecutive trading days, subject to a one year minimum service period prior to vesting.